Xilio Therapeutics, Inc.
XLO
NASDAQ·Healthcare·Biotechnology·Mkt cap $59.2M
$9.00
▼ -0.22%
P/E
-6.04
Mkt Cap
$59.2M
52-Wk Range
$6.47–$12.74
52-Week Range
$6.47 - $12.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 7.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta -0.1).
Growth
Revenue decline expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+16.9% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying XLO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 12, 2026
Reported EPS of -$0.33 vs -$0.59 consensus (+44.1% surprise). Revenue of $18.7M vs $12.7M expected (+47.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+44.1%
Revenue trend · last 8Q
—
—
—
—
+743%
+694%
+332%
+131%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.3M
$1.7M
$2.9M
$8.1M
$19.1M
$13.7M
$12.6M
$18.7M
Margins · last 8Q
Gross
0.0%
Operating
-18.7%
Profit
0.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How XLO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.